Replies to post #136348 on Biotech Values

[DewDiligence]

Something seems to have happened at the last minute. There was elevator music playing on and on for hours…

Wow—this is even more bizarre than I figured.

[DewDiligence]

Rescheduled SRDX CC 2/6/11 @10am ET:

http://finance.yahoo.com/news/SurModics-Announces-bw-623493931.html?x=0

[DewDiligence]

SRDX realigns top management:

http://finance.yahoo.com/news/surmodics-announces-organizational-changes-203000837.html

I owned SRDX in its heyday when it was deriving substantial royalties from JNJ’s now-defunct Cypher stent. However, after SRDX failed in various ophthalmology programs—including a program to deliver sustain-release Lucentis via an implant (#msg-57844827, #msg-32241114)—I lost interest and stopped following the company.

With an enterprise value of ~$250M, perhaps this solidly profitable company is worth another look.